CPC A61K 38/1709 (2013.01) [A61K 8/64 (2013.01); A61K 9/0019 (2013.01); A61K 9/0046 (2013.01); A61K 35/761 (2013.01); A61K 38/17 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); A61K 48/0075 (2013.01); A61Q 19/02 (2013.01); A61Q 19/08 (2013.01); C12N 7/00 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01); A61K 2800/91 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2710/10021 (2013.01); C12N 2710/10043 (2013.01); C12N 2750/14143 (2013.01)] | 17 Claims |
1. A method of gene therapy for Usher syndrome, comprising administering an effective amount of a vector comprising a coding sequence for an USH1 gene product, which is the SANS gene product, to a subject in need thereof.
|